Oral administration of oligo fucoidan improves the survival rate, quality of life, and immunity in patients with lung cancer

Tu-Chen  Liu; Chia-Ju  Shih; Ya-Ling Chiou

doi:10.29219/fnr.v68.10674

Tu-Chen Liu Department of Chest Medicine, Cheng-Ching General Hospital, Taichung, Republic of China
Chia-Ju Shih Department of Nutrition (Master Program), Hungkuang University, Taichung, Taiwan, Republic of China
Ya-Ling Chiou Department of Nutrition (Master Program), Hungkuang University, Taichung, Taiwan, Republic of China

DOI: https://doi.org/10.29219/fnr.v68.10674

Keywords: non-small cell lung cancer, oligo-fucoidan, survival rate, quality of life, immunity

Abstract

ackground: Lung cancer, the most commonly diagnosed cancer globally, has the highest incidence and mortality rates in Taiwan. It can be divided into two types. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers, which is further divided into adenocarcinoma, squamous cell carcinoma, and large cell lung cancer accounting for approximately 40%, 25%, and 15% of NSCLC cases, respectively. Small cell lung cancer accounts for approximately 15% of lung cancers. Early systemic therapy NSCLC was based on chemotherapy, and immunotherapy is currently under development. Fucoidan, from brown seaweed extracts, shows promise in mitigating radiation-induced lung fibrosis in animal studies, suggesting its potential as an adjuvant for radiation therapy-related lung fibrosis in lung cancer patients. However, the clinical utility of such adjuvant therapy in lung cancer treatment remains uncertain. The purpose of this study was to investigate the effects of oral administration of oligo-fucoidan on the survival rate, quality of life, and immunity of patients with lung cancer.

Methods: Subjects with Non-small cell lung cancer aged between 20 and 80 were collected from outpatient clinics, divided into control group (n = 7): conventional therapy and fucoidan group (n = 13): received conventional therapy+ oral supplementation of oligo-fucoidan (550 mg × 4 tablets). Data were collected before the study, at weeks 4, 12, and 24 during the study, and to collect 20 ml of peripheral blood, for analysis biochemical data, liver and kidney function, lymphocyte population, inflammation cytokines, and using EORTC QLQ-C30 questionnaire to assess quality of life.

Results: The survival rates of the subjects in the control and fucoidan groups were 20% and 28.6%, respectively. During the study, patients in the fucoidan group experienced a better quality of life than those in the control group, but this difference lacked statistical significance. Oligo-fucoidan increases the CD19 lymphocyte population. The patients in the fucoidan group also had Lower inflammatory cytokine.

Conclusion: Oligo-fucoidan holds promise as an adjuvant therapy to enhance the survival rate, quality of life, and immune function in patients with lung cancer.

Downloads

Download data is not yet available.

References

1.
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 2019; 28(10): 1563–79. doi: 10.1158/1055-9965.EPI-19-0221

2.
Luo YH, Chiu CH, Scott Kuo CH, Chou TY, Yeh YC, Hsu HS, et al. Lung cancer in Republic of China. J Thorac Oncol 2021; 16(4): 519–27. doi: 10.1016/j.jtho.2020.10.155

3.
Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014; 9(11): 1618–24. doi: 10.1097/JTO.0000000000000334

4.
Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2017; 12(7): 1109–21. doi: 10.1016/j.jtho.2017.04.011

5.
Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007; 11(2): 89–96. doi: 10.1016/j.anndiagpath.2006.04.006

6.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92–8. doi: 10.1056/NEJMoa011954

7.
Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33(1): 9–23. doi: 10.1016/j.ctrv.2006.09.006

8.
Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 2016; 21(5): 634–42. doi: 10.1634/theoncologist.2015-0507

9.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372(21): 2018–28. doi: 10.1056/NEJMoa1501824

10.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389(10066): 255–65. doi: 10.1016/S0140-6736(16)32517-X

11.
Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005; 2(4): 202–10. doi: 10.1038/ncponc0140

12.
Kusaykin M, Bakunina I, Sova V, Ermakova S, Kuznetsova T, Besednova N, et al. Structure, biological activity, and enzymatic transformation of fucoidans from the brown seaweeds. Biotechnol J 2008; 3(7): 904–15. doi: 10.1002/biot.200700054

13.
Li B, Lu F, Wei X, Zhao R. Fucoidan: structure and bioactivity. Molecules 2008; 13(8): 1671–95. doi: 10.3390/molecules13081671

14.
Wang J, Zhang Q, Zhang Z, Li Z. Antioxidant activity of sulfated polysaccharide fractions extracted from Laminaria japonica. Int J Biol Macromol 2008; 42(2): 127–32. doi: 10.1016/j.ijbiomac.2007.10.003

15.
Hsu HY, Lin TY, Lu MK, Leng PJ, Tsao SM, Wu YC. Fucoidan induces toll-like receptor 4-regulated reactive oxygen species and promotes endoplasmic reticulum stress-mediated apoptosis in lung cancer. Sci Rep 2017; 7: 44990. doi: 10.1038/srep44990

16.
Yu HH, Chengchuan Ko E, Chang CL, Yuan KS, Wu ATH, Shan YS, et al. Fucoidan inhibits radiation-induced pneumonitis and lung fibrosis by reducing inflammatory cytokine expression in lung tissues. Mar Drugs 2018; 16(10): 392. doi: 10.3390/md16100392

17.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7–34. doi: 10.3322/caac.21551

18.
Hsu JC, Wei CF, Yang SC, Lin PC, Lee YC, Lu CY. Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open 2020; 10(5): e033427. doi: 10.1136/bmjopen-2019-033427

19.
Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30). J Epidemiol 2004; 14(6): 193–203. doi: 10.2188/jea.14.193

20.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365–76. doi: 10.1093/jnci/85.5.365

21.
Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest 1998; 113(2): 467–81. doi: 10.1378/chest.113.2.467

22.
Franceschini J, Santos AA, El Mouallem I, Jamnik S, Uehara C, Fernandes AL, et al. [Assessment of the quality of life of patients with lung cancer using the medical outcomes study 36-item short-form health survey]. J Bras Pneumol 2008; 34(6): 387–93. doi: 10.1590/s1806-37132008000600009

23.
Lee LJ, Chung CW, Chang YY, Lee YC, Yang CH, Liou SH, et al. Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls. Qual Life Res 2011; 20(3): 415–23. doi: 10.1007/s11136-010-9761-y

24.
Grande GE, Farquhar MC, Barclay SI, Todd CJ. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients. Palliat Support Care 2009; 7(3): 289–97. doi: 10.1017/S1478951509990216

25.
Hollen PJ, Gralla RJ, Cox C, Eberly SW, Kris MG. A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer 1997; 18(2): 119–36. doi: 10.1016/s0169-5002(97)00059-7

26.
Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, Danielson E. The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manage 2007; 34(4): 370–9. doi: 10.1016/j.jpainsymman.2006.12.005

27.
Ostroff JS, Krebs P, Coups EJ, Burkhalter JE, Feinstein MB, Steingart RM, et al. Health-related quality of life among early-stage, non-small cell, lung cancer survivors. Lung Cancer 2011; 71(1): 103–8. doi: 10.1016/j.lungcan.2010.04.011

28.
Broberger E, Sprangers M, Tishelman C. Do internal standards of quality of life change in lung cancer patients? Nurs Res 2006; 55(4): 274–82. doi: 10.1097/00006199-200607000-00008

29.
Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005; 23(35): 8959–67. doi: 10.1200/JCO.2005.01.4910

30.
Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205. doi: 10.1186/1479-5876-10-205

31.
Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res 2011; 167(2): 207–10. doi: 10.1016/j.jss.2009.08.029

32.
Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res 2011; 171(1): 1–5. doi: 10.1016/j.jss.2011.03.068

33.
Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010; 69(3): 348–54. doi: 10.1016/j.lungcan.2009.11.013

34.
Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol 2015; 10(7): 974–84. doi: 10.1097/JTO.0000000000000551

35.
Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight 2016; 1(14): e89014. doi: 10.1172/jci.insight.89014

36.
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26(27): 4410–17. doi: 10.1200/JCO.2007.15.0284

37.
Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014; 189(7): 832–44. doi: 10.1164/rccm.201309-1611OC

38.
Zhang E, Ding C, Li S, Zhou X, Aikemu B, Fan X, et al. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark Res 2023; 11(1): 28. doi: 10.1186/s40364-023-00460-1

39.
Bluml S, McKeever K, Ettinger R, Smolen J, Herbst R. B-cell targeted therapeutics in clinical development. Arthritis Res Ther 2013; 15(Suppl 1): S4. doi: 10.1186/ar3906

40.
Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106(6): dju124. doi: 10.1093/jnci/dju124

41.
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111: 176–81. doi: 10.1016/j.lungcan.2017.07.024